Community Trust & Investment Co. Acquires 34,005 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Community Trust & Investment Co. increased its holdings in IQVIA Holdings Inc. by 42.8% in the second quarter, now owning approximately 0.07% of the company worth $17.88 million.
• Analysts are bullish on IQVIA, with a consensus rating of "Moderate Buy" and an average price target of $229.64, reflecting a strong positive sentiment towards the stock.
• Insider transactions included significant sales by executives, with one insider, Eric Sherbet, selling 5,800 shares for over $1.1 million, reflecting a decrease in ownership by 17.59%.

Community Trust & Investment Co. increased its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 42.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 113,439 shares of the medical research company's stock after acquiring an additional 34,005 shares during the period. Community Trust & Investment Co. owned approximately 0.07% of IQVIA worth $17,877,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. American National Bank & Trust acquired a new stake in shares of IQVIA in the 1st quarter worth about $26,000. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after acquiring an additional 131 shares during the period. Golden State Wealth Management LLC increased its holdings in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after acquiring an additional 130 shares during the period. AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA in the 1st quarter worth about $33,000. Finally, ST Germain D J Co. Inc. increased its stake in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after buying an additional 76 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Trading Down 1.5%

Shares of IQV traded down $2.91 during midday trading on Friday, hitting $187.29. The stock had a trading volume of 2,104,117 shares, compared to its average volume of 1,124,593. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $245.20. The business has a 50-day simple moving average of $184.79 and a two-hundred day simple moving average of $167.44. The firm has a market cap of $31.84 billion, a P/E ratio of 27.10, a price-to-earnings-growth ratio of 2.09 and a beta of 1.32. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same period last year, the company posted $2.64 earnings per share. The business's revenue for the quarter was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

IQV has been the topic of several research analyst reports. Truist Financial raised their target price on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Citigroup reissued a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Barclays raised their target price on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Jefferies Financial Group raised shares of IQVIA from a "hold" rating to a "buy" rating and raised their target price for the company from $195.00 to $225.00 in a research note on Tuesday, September 9th. Finally, William Blair restated an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Eighteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, IQVIA currently has an average rating of "Moderate Buy" and a consensus price target of $229.64.

Insider Activity at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.